Exploring optimal research dosing for growth hormone secretagogues: pulsatile vs. sustained release

Posted by biohackguy72 in Dosing and Protocols

Hey everyone, I have been digging into the literature on growth hormone secretagogues (GHS) for research purposes and I am finding some conflicting data regarding dosing strategies. Specifically, I am curious about the potential differences in efficacy between pulsatile dosing and a more sustained release approach. From what I understand, natural GH release is pulsatile, so mimicking that seems intuitive. However, some studies suggest that maintaining elevated levels of GHS could lead to greater overall GH production, even if it is not perfectly physiological. I am trying to wrap my head around the pharmacokinetics and receptor desensitization aspects here. Has anyone in their research explored this directly with compounds like GHRP 2 or Ipamorelin? I am looking for any insights or anecdotal observations from your own research protocols. What have you found to be more effective in terms of GH upregulation and downstream effects in your research subjects? Are there specific GHS compounds that respond better to one method over the other? Any data points or theoretical discussions would be greatly appreciated. This is purely for research and educational purposes, not for human consumption.

10 Comments

protocol88

I think the type of GHS matters a lot here. Some might be more prone to desensitization than others. Ipamorelin, for example, is often touted as being less prone to it. Has anyone compared pulsatile vs. sustained with Ipamorelin specifically?

peptidehawk27

I have seen the opposite in my own research. A more sustained approach, perhaps with a longer acting GHS or multiple smaller doses throughout the day, led to higher overall IGF 1 levels in my subjects. That suggests better long term anabolism. Pulsatile might be good for a quick burst but not for consistent elevation.

ligandden

It is a balance. You want to stimulate but not overstimulate. I lean towards pulsatile for long term research protocols to preserve receptor function. Short term, sustained might give a bigger initial punch but that is not always the goal.

rust_pdx86

Simpler to administer, yes, but at what cost to the biological feedback loops? My research strongly suggests that the body responds better to natural rhythms. Overriding that with constant stimulation can have unforeseen consequences in the long run.

clinicalwolf

From my research, pulsatile dosing with GHRP 2 seems to yield better results for acute GH spikes. It really mimics the body's natural rhythm which I think is key for avoiding receptor fatigue. Sustained release might lead to some desensitization over time.

grayowl0

I have found that combining both can be effective. A few pulsatile doses to kickstart things and then a lower, sustained dose to maintain elevated levels. It is a bit more complex to protocol but the results in my research subjects have been promising.

biohackguy72

That is exactly what I am trying to figure out. Is the goal to mimic natural physiology or to maximize total exposure? And what are the long term implications of each for receptor sensitivity? Any specific data on that desensitization with sustained release?

nodeclub

It really depends on what you are trying to achieve in your research. For mimicking natural physiology, pulsatile is the way to go. For maximum overall GH exposure, sustained might be better but you run the risk of desensitization as mentioned.

echomind

My research with Ipamorelin showed good results with pulsatile dosing. The subjects maintained sensitivity over longer research periods. When I tried a more sustained approach, I did notice a drop off in response after a few weeks.

vialfiles

I am in the sustained release camp. My research indicates that even with some theoretical desensitization, the sheer volume of GH released with a consistent presence of the secretagogue outweighs the benefits of short bursts. Plus, it is simpler to administer.